What is Automera?
Automated by a focus on autophagy-targeting chimera small molecules, known as AUTACs, Automera occupies a specialized niche within the biopharmaceutical landscape. By leveraging the body's natural cellular degradation pathways, the company aims to develop novel treatments for diseases that have historically been considered undruggable. This mechanism of action represents a significant shift in therapeutic strategy, moving beyond traditional protein inhibition to active protein degradation. Based in Seattle, the company operates at the intersection of molecular biology and precision medicine, positioning itself as a high-growth entity within the competitive biotechnology sector. Their platform is designed to address complex biological targets, offering a scalable solution for addressing unmet medical needs across oncology and neurodegenerative conditions.
How much funding has Automera raised?
Automera has raised a total of $16M across 1 funding round:
Series A
$16M
Series A (2023): $16M with participation from EDBI and Xora Innovation
Key Investors in Automera
EDBI
EDBI is a global investor based in Singapore, focusing on high-growth technology sectors since 1991. The company aims to create value and empower businesses to build sustainable legacies through strategic investments.
Xora Innovation
Xora provides capital and support to deep tech entrepreneurs focused on transforming essential industries, with a specific concentration on sectors like climate energy and AI in physical industries.
What's next for Automera?
The infusion of capital from this major strategic investment will be primarily directed toward expanding the company's internal research capabilities and scaling its AUTAC platform. As Automera moves into its next phase of growth, the focus will likely shift toward establishing strategic partnerships with larger pharmaceutical entities and advancing lead candidates toward preclinical milestones. The involvement of sophisticated institutional backers suggests a long-term commitment to building a sustainable pipeline of therapeutic assets. By maintaining a rigorous focus on scientific excellence and operational efficiency, Automera is poised to become a key player in the next generation of targeted protein degradation therapies, potentially reshaping the standard of care for complex human diseases.
See full Automera company page
